Log in to your Inderes Free account to see all free content on this page.
Lipum
10.5 SEK +2.94%Be the first to follow this company
Lipum is a biopharmaceutical company. The company is in the clinical phase and specializes in the discovery and development of new treatments for chronic inflammatory diseases. The company's drug candidate is based on an antibody intended to be used in treatments to block a specific molecule in the immune system. The drug candidate is in the clinical phase with preclinical data for rheumatism. The company is also evaluating other inflammatory diseases. Lipum has its operations in Umeå.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
LIPUM
Daily low / high price
9.6 / 10.7
SEK
Market cap
222.73M SEK
Turnover
38.99K SEK
Volume
3.8K
Financial calendar
Interim report
25.10.2024
Annual report
28.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Flerie Invest AB | 56.8 % | 56.8 % |
Crafoordska Stiftelsen | 6.1 % | 6.1 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Lipum AB: BioStock: Lipum's CEO comments on multiple-dose results in phase I
LIPUM REPORTS FURTHER PROGRESS WHERE THE MULTIPLE DOSE PART OF THE PHASE I CLINICAL STUDY IS COMPLETED
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio